FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Francesco Caponigro

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Treatment Outcome

Physiology

Signal Transduction

Co-author Network

Publications

TOP 3
Francesco Perri; Fabio Sandomenico; Angela Argenone; Davide Bosso; carlo buonerba; Antonio Daponte; Giuseppina Della Vittoria Scarpati; Giuseppe Di Lorenzo; Franco Fulciniti; Franco Ionna; Paolo Muto; Francesco Caponigro
Induction docetaxel-cisplatin followed by extended-field radiotherapy in patients with cervical metastases from unknown primary carcinoma.
Francesco Perri; Fabio Sandomenico; Angela Argenone; Antonio Daponte; Franco Fulciniti; Franco Ionna; Francesco Longo; Paolo Muto; Francesco Caponigro
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Francesco Caponigro; D Lorusso; G Fornari; C Barone; Marco Merlano; M Airoldi; M Schena; R MacArthur; Steven D Weitman; M G Jannuzzo; S Crippa; F Fiorentini; A Petroccione; S Comis
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Francesco Caponigro (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Francesco Perri; Fabio Sandomenico; Angela Argenone; Davide Bosso; carlo buonerba; Antonio Daponte; Giuseppina Della Vittoria Scarpati; Giuseppe Di Lorenzo; Franco Fulciniti; Franco Ionna; Paolo Muto; Francesco Caponigro
Induction docetaxel-cisplatin followed by extended-field radiotherapy in patients with cervical metastases from unknown primary carcinoma.
Anticancer research 2013;33(3):1135-9.
2013: Francesco Perri; Fabio Sandomenico; Angela Argenone; Antonio Daponte; Franco Fulciniti; Franco Ionna; Francesco Longo; Paolo Muto; Francesco Caponigro
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Oncology 2013;84(4):251-4.
2010: Francesco Caponigro; D Lorusso; G Fornari; C Barone; Marco Merlano; M Airoldi; M Schena; R MacArthur; Steven D Weitman; M G Jannuzzo; S Crippa; F Fiorentini; A Petroccione; S Comis
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2010;66(2):389-94.
2010: Francesco Caponigro; Francesco Longo; Franco Ionna; Francesco Perri
Treatment approaches to nasopharyngeal carcinoma: a review.
Anti-cancer drugs 2010;21(5):471-7.
2009: Francesco Caponigro; Francesco Longo; Francesco Perri; Franco Ionna
Docetaxel in the management of head and neck cancer.
Anti-cancer drugs 2009;20(8):639-45.
2008: Francesco Caponigro; Carmen Romano; Amalia Milano; Raffaele Solla; Giovanni Franchin; Vincenzo Adamo; Ettore Mari; Brunello Morrica; Stefano Pepe
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck.
Anti-cancer drugs 2008;19(7):739-44.
2008: Francesco Caponigro; Giacomo Cartenì; Jean Pierre Droz; Amalia Milano; Wayne B Davis; Patricia Pollard
Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
Cancer chemotherapy and pharmacology 2008;62(2):209-14.
2007: Amalia Milano; Francesco Longo; Maria Basile; Rosario Vincenzo Iaffaioli; Francesco Caponigro
Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
Oral oncology 2007;43(8):729-34.
2007: Rosario Vincenzo Iaffaioli; A Milano; Francesco Caponigro
Therapy of metastatic bladder carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 6():vi153-6.
2007: Amalia Milano; Vincenzo De Rosa; Rosario Vincenzo Iaffaioli; Francesco Caponigro
Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy.
Expert opinion on therapeutic targets 2007;11(6):771-82.
2007: Amalia Milano; Rosario Vincenzo Iaffaioli; Francesco Caponigro
The proteasome: a worthwhile target for the treatment of solid tumours?
European journal of cancer (Oxford, England : 1990) 2007;43(7):1125-33.
2007: Amalia Milano; Gugliemo Nasti; Rosario Vincenzo Iaffaioli; Francesco Caponigro
First line targeted therapies in breast cancer: focus on bevacizumab.
Biologics : targets & therapy 2007;1(1):3-10.
2006: Francesco Caponigro; Amalia Milano; Alessandro Ottaiano; Rosario Vincenzo Iaffaioli
Epidermal growth factor receptor as a major anticancer drug target.
Expert opinion on therapeutic targets 2006;10(6):877-88.
2006: Amalia Milano; Maria Grazia Chiofalo; Maria Basile; Antonella Salzano de Luna; Luciano Pezzullo; Francesco Caponigro
New molecular targeted therapies in thyroid cancer.
Anti-cancer drugs 2006;17(8):869-79.
2006: Amalia Milano; Gaetano Apice; Ettore Ferrari; Flavio Fazioli; Vincenzo De Rosa; Antonella Salzano de Luna; Rosario Vincenzo Iaffaioli; Francesco Caponigro
New emerging drugs in soft tissue sarcoma.
Critical reviews in oncology/hematology 2006;59(1):74-84.
2006: Francesco Caponigro; Amalia Milano; Maria Basile; Franco Ionna; Rosario Vincenzo Iaffaioli
Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Current opinion in oncology 2006;18(3):247-52.
2006: Nicola Normanno; Antonella De Luca; Caterina Bianco; Luigi Strizzi; Mario Mancino; Monica R Maiello; Adele Carotenuto; Gianfranco De Feo; Francesco Caponigro; David S Salomon
Epidermal growth factor receptor (EGFR) signaling in cancer.
Gene 2006;366(1):2-16.
2006: Gaetano Apice; Amalia Milano; Giovanni Salvatore Bruni; Rosario Vincenzo Iaffaioli; Francesco Caponigro
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Reviews on recent clinical trials 2006;1(1):35-42.
2006: Alfonso Illiano; Ciro Battiloro; Roberta Formato; Rocco Danilo; Anna Tortoriello; Francesco Caponigro; Rosario Vincenzo Iaffaioli
Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer.
Frontiers in bioscience : a journal and virtual library 2006;11():2349-53.
2005: Gaetano Facchini; Francesco Fiore; M Caraglia; R D'Angelo; Guglielmo Nasti; Francesco Caponigro; Roberta Formato; Alfredo Budillon; Rosario Vincenzo Iaffaioli
A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(12):1980-1.
2005: Christine Theodore; Lionel Geoffrois; J B Vermorken; Francesco Caponigro; W Fiedler; Philippe Chollet; Alain Ravaud; G J Peters; Christine de Balincourt; Denis Lacombe; Pierre Fumoleau
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
European journal of cancer (Oxford, England : 1990) 2005;41(8):1150-7.
2005: Michele Caraglia; Alfredo Budillon; Pierosandro Tagliaferri; Monica Marra; Alberto Abbruzzese; Francesco Caponigro
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Current drug targets 2005;6(3):301-23.
2005: Nicola Normanno; Caterina Bianco; Luigi Strizzi; Mario Mancino; Monica R Maiello; Antonella De Luca; Francesco Caponigro; David S Salomon
The ErbB receptors and their ligands in cancer: an overview.
Current drug targets 2005;6(3):243-57.
2005: Francesco Caponigro; Roberta Formato; Michele Caraglia; Nicola Normanno; Rosario Vincenzo Iaffaioli
Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Current opinion in oncology 2005;17(3):212-7.
2005: Francesco Caponigro; Maria Basile; Vincenzo De Rosa; Nicola Normanno
New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Anti-cancer drugs 2005;16(2):211-21.
2005: Francesco Caponigro; Gaetano Facchini; Guglielmo Nasti; Rosario Vincenzo Iaffaioli
Gastric cancer. Treatment of advanced disease and new drugs.
Frontiers in bioscience : a journal and virtual library 2005;10():3122-6.
2005: Nicola Normanno; Antonella De Luca; Monica R Maiello; Mario Mancino; Antonio D'Antonio; Marcella Macaluso; Francesco Caponigro; Antonio Giordano
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development.
Frontiers in bioscience : a journal and virtual library 2005;10():2611-7.
2005: Michele Caraglia; Gaia Giuberti; Monica Marra; Elena Di Gennaro; Gaetano Facchini; Francesco Caponigro; Rosario Vincenzo Iaffaioli; Alfredo Budillon; Alberto Abbruzzese
Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells.
Frontiers in bioscience : a journal and virtual library 2005;10():2566-75.
2005: John F Smyth; S Aamdal; A Awada; Christian Dittrich; Francesco Caponigro; Patrick Schöffski; M Gore; T Lesimple; N Djurasinovic; B Baron; Miroslav Ravic; Pierre Fumoleau; Cornelis J A Punt
Phase II study of E7070 in patients with metastatic melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):158-61.
2005: Francesco Caponigro; Pax Willemse; Roberto Sorio; Anne Floquet; Simon van Belle; Jan Demol; Rosa Tambaro; Alessandro Comandini; Angela Capriati; Sabine Adank; Jantien Wanders
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
Investigational new drugs 2005;23(1):85-9.
2004: Francesco Caponigro; Franco Ionna; Giuseppe Comella
New cytotoxic and molecular-targeted therapies of head and neck tumors.
Current opinion in oncology 2004;16(3):225-30.
2004: Francesco Caponigro
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Anti-cancer drugs 2004;15(4):311-20.
2003: Christian Dittrich; Véronique Dieras; Pierre Kerbrat; Cornelis Punt; Roberto Sorio; Francesco Caponigro; Xavier Paoletti; Christine de Balincourt; Denis Lacombe; Pierre Fumoleau
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
Investigational new drugs 2003;21(3):347-52.
2003: Francesco Caponigro; Marina Casale; Jane Bryce
Farnesyl transferase inhibitors in clinical development.
Expert opinion on investigational drugs 2003;12(6):943-54.
2003: Elena Di Gennaro; Marcella Barbarino; Francesca Bruzzese; Sonya De Lorenzo; Michele Caraglia; Alberto Abbruzzese; Antonio Avallone; Pasquale Comella; Francesco Caponigro; Stefano Pepe; Alfredo Budillon
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Journal of cellular physiology 2003;195(1):139-50.
2003: Xavier Pivot; A Awada; D Gedouin; J Kerger; F Rolland; Didier Cupissol; Francesco Caponigro; Giuseppe Comella; J J Lopez-Pousa; Emmanuel Guardiola; B Giroux; B Gérard; M Schneider
Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(3):373-7.
2003: Christian Dittrich; Bruno Coudert; L Paz-Ares; Francesco Caponigro; Marc Salzberg; T Gamucci; X Paoletti; C Hermans; Denis Lacombe; Pierre Fumoleau
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(3):330-4.
2002: Francesco Caponigro
Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Anti-cancer drugs 2002;13(8):891-7.
2002: MM Borner; P Schoffski; R de Wit; Francesco Caponigro; Giuseppe Comella; A Sulkes; GA Greim; G J Peters; K van der Born; Jantien Wanders; R F de Boer; C Martin; Pierre Fumoleau
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(3):349-58.
2002: Francesco Caponigro; Gerardo Rosati; Patrizia De Rosa; Antonio Avallone; Vincenzo De Rosa; Luigi De Lucia; Pasquale Comella; Giuseppe Comella
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Oncology 2002;63(3):232-8.
2002: Francesco Caponigro; Christian Dittrich; J B Sorensen; J H M Schellens; Florence Duffaud; L Paz Ares; Denis Lacombe; Christine de Balincourt; Pierre Fumoleau
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(1):70-4.
2001: Francesco Caponigro; Antonio Avallone; Alfredo Budillon; Pasquale Comella; Giuseppe Comella
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Anti-cancer drugs 2001;12(6):489-97.
2001: David J Propper; alexander mcdonald; A Man; Parames Thavasu; Frances R Balkwill; Jeremy P Braybrooke; Francesco Caponigro; P Graf; C Dutreix; R Blackie; Stanley B Kaye; Trivadi Ganesan; Denis C Talbot; Adrian L Harris; Chris Twelves
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1485-92.
2001: Francesco Caponigro; E Massa; Luigi Manzione; G Rosati; M Biglietto; Luigi De Lucia; C Sguotti; P Sganga; Antonio Avallone; Pasquale Comella; G Mantovani; Giuseppe Comella
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(2):199-202.
2001: Francesco Caponigro; Antonio Avallone; F Rivellini; Pasquale Comella; Franco Ionna; Vincenzo De Rosa; Giuseppe Comella
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Cancer chemotherapy and pharmacology 2001;47(2):113-6.
2000: Francesco Caponigro; Pasquale Comella; F Rivellini; Antonio Avallone; Alfredo Budillon; Elena Di Gennaro; Nicola Mozzillo; Franco Ionna; Vincenzo De Rosa; Luigi Manzione; Giuseppe Comella
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):575-80.
2000: Francesco Caponigro; Pasquale Comella; Alfredo Budillon; J Bryce; Antonio Avallone; Vincenzo De Rosa; Franco Ionna; Giuseppe Comella
Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):339-42.
1999: Francesco Caponigro; Antonio Avallone; howard mcleod; Giacomo Cartenì; Ferdinando De Vita; Rossana Casaretti; J Morsman; R Blackie; Alfredo Budillon; Luigi De Lucia; Adriano Gravina; Giuseppe Catalano; Pasquale Comella; Giuseppe Comella
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3948-55.
1999: Parames Thavasu; David J Propper; alexander mcdonald; Nicola A Dobbs; Trivadi Ganesan; D Talbot; J Braybrook; Francesco Caponigro; C Hutchison; Chris Twelves; A Man; D Fabbro; A Harris; Frances R Balkwill
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
Cancer research 1999;59(16):3980-4.
1999: Rosario Vincenzo Iaffaioli; Anna Tortoriello; Gaetano Facchini; Francesco Caponigro; M Gentile; Nicola Marzano; Adriano Gravina; P Dimitri; G Costagliola; A Ferraro; Giovanni Ferrante; V De Marino; Alfonso Illiano
Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):921-6.
1999: Francesco Caponigro; Pasquale Comella; P Marcolin; F Russo Spena; M Biglietto; Giacomo Cartenì; Luigi De Lucia; Antonio Avallone; Adriano Gravina; Giuseppe Comella
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
Cancer 1999;85(4):952-9.
1999: Alfredo Budillon; Francesco Caponigro
First international conference on new molecular targets for anticancer therapy, Naples, 22-23 June 1998.
Anti-cancer drugs 1999;10(2):249-56.
1998: Giuseppe Frasci; Pasquale Comella; Giuseppe D'Aiuto; Alfredo Budillon; D Barbarulo; Renato Thomas; Immacolata Capasso; Rossana Casaretti; Antonio Daponte; Francesco Caponigro; Adriano Gravina; Luigi Maiorino; G Caratení; A Gentile; Giuseppe Comella
Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Breast cancer research and treatment 1998;49(1):13-26.
1998: Anna Tortoriello; Gaetano Facchini; Francesco Caponigro; Michele Santangelo; G Benassai; G Persico; A Citarella; M Carola; Nicola Marzano; Rosario Vincenzo Iaffaioli
Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.
Breast cancer research and treatment 1998;47(1):91-7.
1997: Pasquale Comella; Antonio Daponte; Rossana Casaretti; Franco Ionna; Francesco Fiore; F Presutti; Giuseppe Frasci; Francesco Caponigro; Adriano Gravina; AP Parziale; Nicola Mozzillo; Giuseppe Comella
Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1326-9.
1997: Rosario Vincenzo Iaffaioli; Gaetano Facchini; Anna Tortoriello; Francesco Caponigro; Alfonso Illiano; M Gentile; Adriano Gravina; Paolo Muto
Phase I study of vinorelbine and paclitaxel in small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;41(1):86-90.
1996: Rosario Vincenzo Iaffaioli; Francesco Caponigro; Anna Tortoriello; Gaetano Facchini; Vincenzo Ravo; M Maccauro; P Dimitri; F Crovella; P Muto
Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):1901-4.
1996: Rosario Vincenzo Iaffaioli; Gaetano Facchini; Anna Tortoriello; S Scala; R Pacelli; G La Mura; Caterina Pagliarulo; Giovannella Palmieri; Francesco Caponigro
Modulation of chemosensitivity by alpha interferon in multiple myeloma and non-Hodgkin's lymphoma.
Journal of experimental therapeutics & oncology 1996;1(4):226-30.
1995: Rosario Vincenzo Iaffaioli; Anna Tortoriello; Gaetano Facchini; M Santangelo; L Bucci; L Fei; Natale Di Martino; G Mantovani; Francesco Caponigro
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Breast cancer research and treatment 1995;35(3):243-8.
1991: Giovannella Palmieri; Cesare Gridelli; G Airoma; R Pepe; P Incoronato; Francesco Caponigro; Angelo Raffaele Bianco
Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil.
Journal of chemotherapy (Florence, Italy) 1991;3(1):55-60.
1991: Rosario Vincenzo Iaffaioli; Francesco Caponigro; G Esposito; Caterina Pagliarulo; S Deplacido; B Ungaro; L Bazzicalupo; Giuseppe Frasci; Angelo Raffaele Bianco
Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
The International journal of biological markers 1991;6(1):21-4.
1990: Giovannella Palmieri; Francesco Caponigro; Rosario Vincenzo Iaffaioli; Alma Contegiacomo; V Montesarchio; Rossella Lauria; R Calderopoli; Caterina Pagliarulo; Cesare Gridelli; Angelo Raffaele Bianco
CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: final results of a pilot study.
Hematological oncology 1990;8(6):313-22.
1990: Giovannella Palmieri; Rossella Lauria; Francesco Caponigro; Caterina Pagliarulo; V Montesarchio; F Nuzzo; Cesare Gridelli; Angelo Raffaele Bianco
Salvage chemotherapy for non Hodgkin's lymphoma of unfavourable histology with a combination of CCNU and vinblastine.
Hematological oncology 1990;8(4):179-83.
1990: G Palmieri; Pierosandro Tagliaferri; Alma Contegiacomo; Francesco Caponigro; Rosario Vincenzo Iaffaioli; R Calderopoli; Rossella Lauria; V Montesarchio; Angelo Raffaele Bianco
Changing presentation in non-Hodgkin lymphoma.
Lancet 1990;335(8699):1221.
1990: Francesco Caponigro; Rosario Vincenzo Iaffaioli; Caterina Pagliarulo; Sabino De Placido; Giuseppe Frasci; B Ungaro; Elide Matano; Angelo Raffaele Bianco
CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
The International journal of biological markers 1990;5(2):73-6.
1990: Giovannella Palmieri; Cesare Gridelli; R Pepe; G Airoma; Rosario Vincenzo Iaffaioli; Giuseppe Frasci; Francesco Caponigro; Angelo Raffaele Bianco
Partial response of metastatic hepatocellular carcinoma after treatment with thymostimulin.
Tumori 1990;76(1):61-3.
1987: Rosario Vincenzo Iaffaioli; Francesco Caponigro; G Genua; V Montesarchio; B Di Prisco; Angelo Raffaele Bianco
An unusual case of primary hormone-secreting germ cell tumor of the retroperitoneum.
Tumori 1987;73(5):517-21.